Biotech

All Articles

Analysts dig into Avidity's DMD win, showing subtleties in data

.Avidity Biosciences amazed investors with phase 1/2 data in Duchenne muscle dystrophy (DMD) Friday,...

Actinogen's cortisol blocker falls short period 2 clinical depression research

.Actinogen Medical's cortisol blocker has actually overlooked the primary endpoint of a stage 2 rese...

Bivictrix makes a decision going personal only way to take ADC right into medical clinic

.Antibody-drug conjugates (ADCs) have gone to the facility of several a billion-dollar biobuck licen...

TPG leadings up funds to $580M for expenditures across life sciences

.Property manager TPG, which has sustained biotechs such as Sionna Therapeutics as well as Santa Ana...

Merck quits period 3 TIGIT trial in bronchi cancer cells for futility

.Merck &amp Co.'s TIGIT system has suffered an additional obstacle. Months after shuttering a phase ...

After a challenging year, Exscientia folds up in to Recursion

.After a year defined by pipeline cuts, the departure of its own CEO and also layoffs, Exscientia wi...

Cullinan, after $25M bargain, hands back bispecific to Port

.Cullinan Therapeutics was impressed enough with Harbour BioMed's bispecific immune reactor that it ...

A more detailed examine Intense Biotech's Brutal 15

.Within this full week's incident of "The Best Line," our team are actually diving into Fierce Biote...

Lilly encounters stage 2 breakdown of tau-targeting med

.The confetti is actually still soaring coming from Eli Lilly's party commemorating the commendation...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our summary of considerable management hirings, shootings...